Immunotherapy of breast cancer

Expert Opinion on Biological Therapy

Volumn 12, Issue 4, 2012, Pages 479-490

  Wright, Stephen E ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c Harrington Cancer Center   (United States)

Author keywords

Adoptive T cells; Antibodies; Breast cancer; Immune modulatory agents; Immunotherapy; Vaccines

Indexed keywords

AGATOLIMOD; CANCER VACCINE; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; EMEPEPIMUT S; ERTUMAXOMAB; FALIMAREV; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INALIMAREV; INTERLEUKIN 2; IPILIMUMAB; LAPATINIB; MONOCLONAL ANTIBODY; MUCIN 1; NEU DIFFERENTIATION FACTOR; PACLITAXEL; PERTUZUMAB; POLYADENYLIC POLYURIDYLIC ACID; RESIQUIMOD; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR AGONIST; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TUMOR ANTIGEN; TUMOR VACCINE; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 2;

ALLOGENEIC STEM CELL TRANSPLANTATION; BREAST CALCIFICATION; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; HUMAN; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MEDICAL RESEARCH; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; UNINDEXED SEQUENCE;

ANIMALS; BREAST NEOPLASMS; CANCER VACCINES; FEMALE; HUMANS; IMMUNOTHERAPY;

EID: 84858657759     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.665445     Document Type: Review

References (88)

1. Ruttinger D, Winter H, Van den Engel NK, et al. Immunotherapy of cancer: key findings and commentary on the Third Tegernsee Conference. Oncologist 2010;15:112-18
2. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008;222:347-68
3. Beatson RE, Taylor-Papadimitriou J, Burchell JM. MUC1 immunotherapy. Immunotherapy 2010;2:305-27
4. Curigliano G, Spitaleri G, Pietri E, et al. Breast cancer vaccines: a clinical reality or fairy tale? Ann Oncol 2006;17:750-62
5. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. Clin Cancer Res 2009;15:5323-237
6. Cheever MA, Matrisian LM; Report of the Immune Response Modifier Pathway Prioritization Working Group (IRMP WG). A working group of the Clinical Trials and Translational Research Advisory Committee (CTAC). National Cancer Institute, NIH (Presented to CTAC); 4 November 2009. Available from: http://deainfo.nci. nih.gov/advisory/ ctac/workgroup/- IRM%20Prioritization%20Working%20Group%20FINAL%20REPORT.pdf [Last accessed 18 February 2012]
7. Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy 2009;1:949-64
8. Gnjatic S, Sawhney NB, Bhardwaj N. Toll-like receptor agonists: are they good adjuvants? Cancer J 2010;16:382-91
9. Lacour J, Lacour F, Spira A, et al. Adjuvant treatment with polyadenylic-polyuridylic acid (Polya. Polyu) in operable breast cancer. Lancet 1980;2:161-4 (Pubitemid 10084713)
10. Vonderheide RH, LoRusso PM, Khalil M, et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T Cells. Clin Cancer Res 2010;16:3785-94
11. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
12. Memorial Sloan-Kettering Cancer Center. Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer. ClinicalTrials.gov NCT01502592. Available from: http://clinicaltrials.gov/ ct2/show/NCT01502592? erm=NCT01502592&rank=1
13. National Cancer Institute (NCI). National Institutes of Health Clinical Center (CC) CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors. ClinicalTrials.gov NCT01386502. Available from: http://clinicaltrials.gov/ ct2/show/NCT01386502? term=NCT01386502&rank=1
14. Tsuruma T, Iwayama Y, Ohmura T, et al. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J Transl Med 2008;6:24
15. Vonderheide RH, Domchek SM, Schultze JL, et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ lymphocytes. Clin Cancer Res 2004;10:828-40
16. Avigan D, Vasir B, Gong J, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004;10:4699-708 (Pubitemid 38955520)
17. Butts C, North S. Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. Expert Rev Vaccines 2005;4:249-57 (Pubitemid 40978689)
18. Ohyanagi F, Horai T, Sekine I, et al. Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II study. Jpn J Clin Oncol 2011;41:718-22
19. EMD Serono. A Study of Stimuvax in Combination With Hormonal Treatment versus Hormonal Treatment Alone for First-line Therapy of Endocrine-sensitive Advanced Breast Cancer. ClinicalTrials. gov NCT00925548. Available from: http://clinicaltrials.gov/ct2/show/NCT00925548?term=NCT00925548&rank=1
20. Brossart P, Wirths S, Stuhler G, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;96:3102-8
21. Disis ML, Wallace DR, Gooley TA, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009;27:4685-92
22. Norell H, Poschke I, Charo J, et al. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med 2010;8:53
23. Gulley JL, Arlen PM, Tsang K-Y, et al. Pilot Study of vaccination with recombinant CEA-MUC-1-TRICOM Poxviral-based vaccines in patients withmetastatic carcinoma. Clin Cancer Res 2008;14:3060-9
24. National Cancer Institute (NCI), National Institutes of Health Clinical Center (CC). Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer ClinicalTrials.gov NCT00179309. Available from: http:// clinicaltrials.gov/ct2/show/ NCT00179309? term=NCT00179309&rank=1
25. Disis ML, Schiffman K, Guthrie K, et al. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein-based vaccine. J Clin Oncol 2004;22:1916-25 (Pubitemid 41095184)
26. Morse MA, Hobeika A, Osada T, et al. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. J Transl Med 2007;5:42
27. Peoples GE, Holmes JP, Hueman MT, et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2008;14:797-803 (Pubitemid 351231162)
28. Holmes JP, Clifton GT, Patil R, et al. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine. Cancer 2011;117:463-71
29. Apostolopoulos V, Pietersz GA, Tsibanis A, et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res 2006;8(3):R27
30. Tang CK, Katsara M, Apostolopoulos V. Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines 2008;7:963-75
31. Wright SE, Quinlin IS, Rewers-Felkins KA, et al. Retention of immunogenicity produced by mucin 1 peptides with glycosylation site substitutions. Immunopharmacol Immunotoxicol 2010;32:647-55
32. Zwaveling S, Ferreira Mota SC, Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002;169:350-8 (Pubitemid 34686155)
33. Haidopoulos D, Konstadoulakis MM, Antonakis PT, et al. Circulating anti-CEA antibodies in the sera of patientswith breast cancer. Eur J Surg Oncol (EJSO) 2000;26:742-6 (Pubitemid 32059830)
34. Karyampudi L, Krco CJ, Kalli KR, et al. Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen. Cancer Immunol Immunother 2010;59:161-71
35. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92 (Pubitemid 32222155)
36. Marty M, Cognetti F, Maraninchi D, et al. Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-74 (Pubitemid 46207001)
37. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomized controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;365:377-84
38. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011;29:3366-73
39. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72 (Pubitemid 41464705)
40. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84 (Pubitemid 41464706)
41. Morrow PK, Wulf GM, Ensor J, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 2011;29:3126-32
42. Kiewe P, Hasmuller S, Kahlert S, et al. Phase I trial of the trifunctional anti-HER2 Anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 2006;12:3085-91
43. Adams C, Allison D, Flagella K, et al. Humanization of a recombinant monoclonal antibody to produce a herapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 2006;55:717-28
44. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28:1138-44
45. Burris HA, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29:398-405
46. Pegram MD, Borges VF, Ibrahim N, et al. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res 2009;11(5):R73
47. Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI). Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy. ClinicalTrials.gov NCT00066547. Available from: http:// clinicaltrials.gov/ct2/ show/ NCT00066547? term=NCT00066547&rank=1
48. Eibl B, Schwaighofer H, Nachbaur D, et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996;88:1501-8 (Pubitemid 26276829)
49. Ueno NT, Rondon G, Mirza NQ, et al. Allogeneic peripheral-blood progenitorcell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998;16:986-93 (Pubitemid 28108731)
50. Carella AM, Beltrami G, Corsetti MT, et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet 2005;366:318-20 (Pubitemid 41019423)
51. Carella AM, Ferrara R, Orcioni GF, et al. Profound graft-versus-tumor response in metastatic breast cancer with nonmyeloablative allografting. Ann Oncol 2007;18:1751-4 (Pubitemid 47506269)
52. Carella AM, Bregni M. Current role of allogeneic stem cell transplantation in breast cancer. Ann Oncol 2007;18:1591-3 (Pubitemid 47506244)
53. de Souza JA, Davis ML, Rondon G, et al. Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer. Bone Marrow Transplant 2009;44:81-7
54. Fleskens AJHM, Lalisang RI, Bos GMJ, et al. HLA-matched allo-SCT after reduced intensity conditioning with fludarabine/CY in patients with metastatic breast cancer. Bone Marrow Transplant 2010;45:464-7
55. Bishop MR, Fowler DH, Marchigiani D, et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 2004;22:3886-92 (Pubitemid 41079869)
56. Visonneau S, Cesano A, Porter DL, et al. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer. Clin Cancer Res 2000;6:1744-54 (Pubitemid 30305067)
57. Bernhard H, Neudorfer J, Gebhard K, et al. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol Immunother 2008;57:271-80 (Pubitemid 350159915)
58. Peethambaram PP, Melisko ME, Rinn KJ, et al. A Phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/ neu. Clin Cancer Res 2009;15:5937-44
59. Wright SE, Rewers-Felkins KA, Quinlin IS, et al. Tumor burden influences cytotoxic T cell development in metastatic breast cancer patients - a Phase I/II study. Immunol Invest 2009;48:820-38
60. Morgan RA, Dudley ME, Rosenberg SA. Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer J 2010;16:336-41
61. Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843-51
62. Junghans RP. Strategy escalation: an emerging paradigm for safe clinical development of T cell gene therapies. J Transl Med 2010;8:55
63. Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI). Laboratory-Treated T Cells After Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer Undergoing Surgery ClinicalTrials.gov NCT01147016. Available from: http:// clinicaltrials.gov/ct2/show/ NCT01147016? term=NCT01147016&rank=1
64. Perez E, Suman V, Davidson N, et al. Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-Positive adjuvant breast cancer trial. Cancer Res 2009;69(24 Suppl):abstract nr 80
65. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15 (Pubitemid 39273730)
66. New York University School of Medicine, National Cancer Institute (NCI). Toll-like Receptor (TLR) 7 Agonist and Radiotherapy for Breast Cancer With Skin Metastases. ClinicalTrials.gov NCT01421017. Available from: http:// clinicaltrials.gov/ ct2/show/NCT01421017? term=NCT01421017&rank=1
67. Case Comprehensive Cancer Center. MUC1 Vaccine for Triple-negative Breast Cancer. ClinicalTrials.gov NCT00986609. Available from: http:// clinicaltrials.gov/ct2/show/ NCT00986609? term=NCT00986609&rank=1
68. Ohio State University Comprehensive Cancer Center, Pfizer. Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer. ClinicalTrials.gov NCT00824733. Available from: http:// clinicaltrials.gov/ct2/show/ NCT00824733?term=00824733&rank=1
69. Celldex Therapeutics. A Study of CDX-1401 in Patients With Malignancies Known to Express NYESO- 1. ClinicalTrials.gov NCT00948961. Available from: http:// clinicaltrials.gov/ct2/show/ NCT00948961? term=NCT00948961&rank=1
70. Fred Hutchinson Cancer Research Center, National Cancer Institute (NCI). Vaccine Therapy in Combination With Ampligen and/or Sargramostim in Patients With Stage II-IV HER2-Positive Breast Cancer. ClinicalTrials.gov NCT01355393. Available from: http:// clinicaltrials.gov/ct2/show/ NCT01355393? term=NCT01355393&rank=1
71. Ohio State University Comprehensive Cancer Center. Vaccine Therapy in Treating Patients With Metastatic Solid Tumors ClinicalTrials.gov NCT01376505. Available from: http:// clinicaltrials.gov/ct2/show/ NCT01376505? term=NCT01376505&rank=1
72. Fred Hutchinson Cancer Research Center, National Cancer Institute (NCI). Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer. ClinicalTrials.gov NCT00343109. Available from: http:// clinicaltrials.gov/ct2/show/ NCT00343109? term=NCT00343109&rank=
73. Fred Hutchinson Cancer Research Center, National Cancer Institute (NCI). Vaccine Therapy in Treating Patients With Stage IV Breast Cancer ClinicalTrials.gov NCT00791037. Available from: http://clinicaltrials.gov/ ct2/show/NCT00791037? term=NCT00791037&rank=1
74. University of Pennsylvania, National Cancer Institute (NCI). Vaccine Therapy in Treating Patients With Ductal Carcinoma In Situ of the Breast. ClinicalTrials.gov NCT00923143. Available from: http://clinicaltrials.gov/ t2/show/NCT00923143? term=NCT00923143&rank=1
75. UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI). Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer. ClinicalTrials.gov NCT00266110. Available from: http:// clinicaltrials.gov/ct2/show/ NCT00266110? term=NCT00266110&rank=1
76. Galena Biopharma, Inc. Efficacy and Safety Study of NeuVax(TM) Vaccine to Prevent Breast Cancer Recurrence. ClinicalTrials.gov NCT01479244. Available from: http://clinicaltrials.gov/ ct2/show/NCT01479244? term= NCT01479244&rank=1
77. Brooke Army Medical Center, Antigen Express, Inc. Walter Reed Army Medical Center Vaccine Therapy in Treating Patients With Breast CancerClinicalTrials.gov NCT00524277. Available from: http://clinicaltrials.gov/ ct2/show/NCT00524277? term=NCT00524277&rank=1
78. University of Virginia, National Institutes of Health (NIH). Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer ClinicalTrials.gov NCT00892567. Available from: http://clinicaltrials.gov/ ct2/show/NCT00892567? term=NCT00892567&rank=1
79. Sidney Kimmel Comprehensive Cancer Center, National Cancer Institute (NCI). Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer ClinicalTrials.gov NCT00847171. Available from: http:// clinicaltrials.gov/ct2/show/ NCT00847171? term=NCT00847171&rank=1
80. Sidney Kimmel Comprehensive Cancer Center, National Cancer Institute (NCI). Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer ClinicalTrials.gov NCT00971737. Available from: http:// clinicaltrials.gov/ct2/show/ NCT00971737? term=NCT00971737&rank=1
81. Hoffmann-La Roche, Genentech. A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE) ClinicalTrials.gov NCT01120184. Available from: http://clinicaltrials.gov/ ct2/show/NCT01120184? term=NCT01120184&rank=1
82. Hoffmann-La Roche, Breast International Group, Genentech. A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer. ClinicalTrials.gov NCT01358877. Available from: http:// clinicaltrials.gov/ct2/show/ NCT01358877? erm=NCT01358877&rank=1
83. Genentech. An Open-Label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine+Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer (EMILIA) ClinicalTrials.gov NCT00829166. Available from: http://clinicaltrials.gov/ ct2/show/NCT00829166? term= NCT00829166&rank=1
84. Scripps Health. Nonmyeloablative Allogeneic Transplant ClinicalTrials.gov NCT01272817. Available from: http:// clinicaltrials.gov/ct2/show/ NCT01272817? term=NCT01272817&rank=1
85. Fred Hutchinson Cancer Research Center, National Cancer Institute (NCI). Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant. ClinicalTrials.gov NCT00096161. Available from: http:// clinicaltrials.gov/ct2/show/ NCT00096161? term=NCT00096161&rank=1
86. Fred Hutchinson Cancer Research Center, National Cancer Institute (NCI). Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant ClinicalTrials.gov NCT00068718. Available from: http://clinicaltrials.gov/ ct2/show/NCT00068718? term=NCT00068718&rank=1
87. Jiang Li, Sun Yat-sen University. A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors. ClinicalTrials.gov NCT01462903. Available from: http://clinicaltrials.gov/ ct2/show/NCT01462903? term=NCT01462903&rank=1
88. Cancer Research UK, National Cancer Institute (NCI). Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer. ClinicalTrials.gov NCT01212887. Available from: http:// clinicaltrials.gov/ct2/show/ NCT01212887? term=NCT01212887&rank=1